Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The mitogen-activated protein kinase (MAPK) signaling pathway is frequently altered in cancer.
• Mutations in RAF components of the MAPK pathway lead to its auto-activation, driving uncontrolled cell proliferation.
• RAF signaling is a critical target for anti-cancer drug development.

Purpose of the Study:

• To review recent investigations of RAF inhibitors over the last five years.
• To highlight the development of diverse chemical scaffolds targeting the RAF component.
• To summarize the anti-cancer activity of identified RAF inhibitors.

Main Methods:

• Literature review of scientific publications from the last five years.
• Analysis of studies reporting on RAF inhibitors and their chemical scaffolds.
• Evaluation of reported anti-cancer activities and mechanisms of action.

Main Results:

• Numerous chemical scaffolds targeting RAF have been identified.
• Many of these RAF inhibitors demonstrate significant anti-cancer potency.
• Recent research has expanded the landscape of RAF-targeted therapies.

Conclusions:

• RAF inhibitors represent a promising therapeutic strategy for cancers driven by MAPK pathway mutations.
• Continued investigation into novel chemical scaffolds is crucial for advancing RAF-targeted cancer treatments.
• The development of effective RAF inhibitors holds potential for controlling tumor growth and proliferation.